Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab
IntroductionL-Tryptophan (Trp) metabolism is impaired across various chronic inflammatory pathologies, including Multiple Sclerosis (MS). Trp processing relies on three metabolic routes, namely Kynurenine, Serotonin and Indole pathways. The host microbiota significantly impacts Trp metabolism, prima...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1603663/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849727135617384448 |
|---|---|
| author | Carolina Ricci Matteo Pivetta Eleonora Martinis Viviana Valeri Carolina Colliva Nicola Giacchè Simone Lorenzut Daniela Cargnelutti Barbara Frossi Silvia Tonon |
| author_facet | Carolina Ricci Matteo Pivetta Eleonora Martinis Viviana Valeri Carolina Colliva Nicola Giacchè Simone Lorenzut Daniela Cargnelutti Barbara Frossi Silvia Tonon |
| author_sort | Carolina Ricci |
| collection | DOAJ |
| description | IntroductionL-Tryptophan (Trp) metabolism is impaired across various chronic inflammatory pathologies, including Multiple Sclerosis (MS). Trp processing relies on three metabolic routes, namely Kynurenine, Serotonin and Indole pathways. The host microbiota significantly impacts Trp metabolism, primarily by being responsible for Indole metabolites production and secondarily by shaping both Kynurenine and Serotonin pathways. Pathological conditions and pharmaceutical treatments can elicit changes in microbial populations, leading to alterations in metabolites production and therefore determining rearrangements in host metabolism. Currently, no simultaneous exploration and comparison of all three Trp related metabolic routes has been performed in the context of MS patients before and after Ocrelizumab (OCR) treatment.MethodsBy performing mass spectrometry on plasma samples collected from healthy controls and MS patients before and six months after OCR treatment we provided a comparative investigation of Trp metabolomics profile.Results and discussionOur data points out to concurrent alterations of Trp-related pathways among both OCR treated and untreated MS patients. Furthermore, MS treated patients presented a pattern resembling health state for various metabolites across the pathways. The results reported in our research may contribute to unveiling new perspectives and understanding regarding MS pathogenetic mechanisms. |
| format | Article |
| id | doaj-art-f2ccc7865dc74f56a1cdc9ce171d0bcf |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f2ccc7865dc74f56a1cdc9ce171d0bcf2025-08-20T03:09:57ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-06-011610.3389/fimmu.2025.16036631603663Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumabCarolina Ricci0Matteo Pivetta1Eleonora Martinis2Viviana Valeri3Carolina Colliva4Nicola Giacchè5Simone Lorenzut6Daniela Cargnelutti7Barbara Frossi8Silvia Tonon9Department of Medicine, University of Udine, Udine, ItalyDepartment of Medicine, University of Udine, Udine, ItalyDepartment of Medicine, University of Udine, Udine, ItalyDepartment of Medicine, University of Udine, Udine, ItalyTes Pharma S.r.l., Corciano, ItalyTes Pharma S.r.l., Corciano, ItalyNeurology Unit, “Head, Neck and Neurosciences” Department, University Hospital of Udine, Udine, ItalyNeurology Unit, “Head, Neck and Neurosciences” Department, University Hospital of Udine, Udine, ItalyDepartment of Medicine, University of Udine, Udine, ItalyDepartment of Medicine, University of Udine, Udine, ItalyIntroductionL-Tryptophan (Trp) metabolism is impaired across various chronic inflammatory pathologies, including Multiple Sclerosis (MS). Trp processing relies on three metabolic routes, namely Kynurenine, Serotonin and Indole pathways. The host microbiota significantly impacts Trp metabolism, primarily by being responsible for Indole metabolites production and secondarily by shaping both Kynurenine and Serotonin pathways. Pathological conditions and pharmaceutical treatments can elicit changes in microbial populations, leading to alterations in metabolites production and therefore determining rearrangements in host metabolism. Currently, no simultaneous exploration and comparison of all three Trp related metabolic routes has been performed in the context of MS patients before and after Ocrelizumab (OCR) treatment.MethodsBy performing mass spectrometry on plasma samples collected from healthy controls and MS patients before and six months after OCR treatment we provided a comparative investigation of Trp metabolomics profile.Results and discussionOur data points out to concurrent alterations of Trp-related pathways among both OCR treated and untreated MS patients. Furthermore, MS treated patients presented a pattern resembling health state for various metabolites across the pathways. The results reported in our research may contribute to unveiling new perspectives and understanding regarding MS pathogenetic mechanisms.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1603663/fullmultiple sclerosisocrelizumabtryptophankynurenineserotoninindole |
| spellingShingle | Carolina Ricci Matteo Pivetta Eleonora Martinis Viviana Valeri Carolina Colliva Nicola Giacchè Simone Lorenzut Daniela Cargnelutti Barbara Frossi Silvia Tonon Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab Frontiers in Immunology multiple sclerosis ocrelizumab tryptophan kynurenine serotonin indole |
| title | Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| title_full | Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| title_fullStr | Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| title_full_unstemmed | Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| title_short | Tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| title_sort | tryptophan pathway profiling in multiple sclerosis patients treated with ocrelizumab |
| topic | multiple sclerosis ocrelizumab tryptophan kynurenine serotonin indole |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1603663/full |
| work_keys_str_mv | AT carolinaricci tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT matteopivetta tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT eleonoramartinis tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT vivianavaleri tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT carolinacolliva tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT nicolagiacche tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT simonelorenzut tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT danielacargnelutti tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT barbarafrossi tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab AT silviatonon tryptophanpathwayprofilinginmultiplesclerosispatientstreatedwithocrelizumab |